entered the 21st century, my country's medical innovation wave continued to rush forward, and the big health industry also ushered in rapid development. According to data from the China Business Industry Research Institute, the total output value of the domestic health industry in 2017 has reached about 6 trillion yuan, and it is expected to exceed 8 trillion yuan in 2020.
In this context, the big health industry is becoming the top priority of local governments' economic planning. Especially under the influence of the new crown pneumonia epidemic this year, the bias of this plan has become more and more obvious. As an important carrier of medical innovation, has become a general consensus in most cities to build a competitive life science park. Many cities even integrate the strength of the whole city and the province to develop life science parks.
However, the market is changing and the demands of innovative companies are also changing. How can better carry out the whole chain service of project cultivation, business incubation, and industry cultivation has become the direction of concern and thinking of local governments and various parks. In this trend of , many parks are trying new methods and new paths. Among them, the Wuxi International Life Science Innovation Park (hereinafter referred to as "I·Campus") jointly built by the Wuxi Municipal Government, Wuxi High-tech Zone and AstraZeneca is a high-quality sample worthy of attention.
At the 3rd China International Import Expo (hereinafter referred to as the "CIIE") held from November 5th to 10th, I·Campus, which opened only one year ago, handed in a dazzling answer sheet.
At the third CIIE, 12 innovative companies signed contracts to settle in the Wuxi International Life Science Innovation Park.
First, 12 medical innovation companies with unique advantages signed contracts to settle in this CIIE. Friends of the International Life Science Innovation Park The circle" keeps expanding. includes UST, a US high-tech biotechnology company focusing on the development of gene sequencing platforms, Best of China, a leading innovative drug clinical development institution, and Zero Krypton Technology, a domestic unicorn enterprise in the field of medical big data and artificial intelligence. 's newly settled companies cover multiple fields such as new drug research and development, gene sequencing, smart wearables, medical big data, and Internet hospitals.
Second, a number of companies that have settled in have also achieved significant milestone progress. : Qiyi Medical entered the park at the beginning of the year and became a partner of AstraZeneca’s "Respiratory and Airway Chronic Disease Management" project, promoting the development of respiratory risk screening More than 470 hospitals have been widely deployed, and have received investment from first-line USD funds; Guanhe Medicine ushered in the opening of "Wuxi Guanhe Medical Laboratory" in just two months, and successfully obtained the qualification of medical testing laboratory in early August. And it has reached a joint development and commercialization cooperation for companion diagnostics with AstraZeneca...
AstraZeneca and I·Campus companies appeared at the third CIIE
Judging from the achievements, I·Campus is continuing to attract from Global high-quality innovative companies, and settled companies are constantly reaching new cooperation and achieving new breakthroughs. What is unique about I·Campus? How does it empower enterprises? What will be the future strategic layout? In response to these issues, Artery.com interviewed relevant persons in charge of AstraZeneca, established companies and newly contracted companies to get a glimpse. How does
I·Campus do it behind the fruitful medical innovation achievements of
? As a center of innovation and entrepreneurship, the basic attribute of the park is to provide enterprises with a space suitable for their current development. This includes both the physical space and the ecological space for entrepreneurship. Therefore, factors such as partners, regional location, policy support, space area, and supporting facilities will affect the enthusiasm of settled enterprises and the effect of follow-up services.
first look at the partners. Unlike most domestic life science parks, I·Campus is my country’s first industrial park jointly built by a multinational head life science company and the government, with very distinctive international and innovative features.
"As a leading life science company in the world, AstraZeneca has extensive innovation resources and a global network. With 27 years of entry into China, AstraZeneca has a deep understanding and rich practical experience in the Chinese market. " Xu Jing, vice president of Silicon China and head of the Digitalization and Business Innovation Department, told Artery.com that relies on AstraZeneca's omni-channel commercialization platform, and I·Campus companies can get rich commercialization-related assistance. includes consulting AstraZeneca's internal experts, solution integration, commercialization cooperation, etc.
It is worth mentioning that, thanks to AstraZeneca’s rich global innovation network, I·Campus can introduce foreign start-ups to China, so that the park enterprises have the opportunity to carry out global operations with the support of AstraZeneca’s global network. expand. As of now, there are more than 15 AstraZeneca International Innovation Centers worldwide, with locations in the United States, Brazil, Argentina, Sweden, the United Kingdom, France, Israel, Russia, South Korea, India, Singapore, etc. In terms of
policy, Wuxi Municipal Government and Wuxi High-tech Zone Government have brought a package of incentive policies for l·Campus settled enterprises. includes medical equipment research and development subsidies, equipment purchase subsidies, intellectual property rewards, talent subsidies, recruitment support, etc. For medical innovation companies, approval has always been a very important link. In response to this, the Jiangsu Provincial Drug Administration and the Wuxi Municipal Government have set up the "Wuxi High-tech Zone Biomedical Industry Innovation and Development Service Center" in I·Campus to guide the professional approval process, and opened a "green window for medical equipment access" for settled enterprises ", creating a service channel for rapid review and approval.
Not only that, At this CIIE, the Wuxi Medical Insurance Bureau and Wuxi High-tech Zone signed a strategic framework agreement , planning to set up a "Wuxi Pharmaceutical Bidding and Purchasing Center New District Workstation" in the Innovation Park, is the park's innovative medical equipment and medical The incubation of health solutions strives for more policy support and resource protection. "I·Campus Foreign Affairs Service Station" was also officially inaugurated. will create a "green channel" for talent introduction and foreign affairs services in the park. will help the innovation park build an international community, improve the level of internationalization, and further attract overseas innovative projects. The "Wuxi European Life Science Innovation Industrial Park" was also unveiled on the same day, and provided support for enterprises in the park to expand international cooperation. In addition, the "Wuxi Biomedical Industry Association" and the "China-Europe Alumni Medical and Health Industry Association" signed a contract to settle in the park at the CIIE, and the "CCHRPP Wuxi Medical Research and Certification Center" was inaugurated simultaneously. aims to improve the park from scientific research to industrialization. The medical innovation ecosystem provided further support.
After solving the policy problem, the next thing the park needs to solve for the enterprise is the funding problem. "Life science companies have a large demand for funds for years of continuous R&D cycles. The global medical industry fund jointly established by AstraZeneca and CICC Capital will continue to provide potential projects including I·Campus Financing.” Xu Jing said that I·Campus also cooperates with top investment institutions such as Eli Lilly Asia Fund, Legend Capital, Legend Star, and Qiming Venture Capital to continuously meet the funding needs of innovative companies at all stages.
In addition, industry collaboration is also crucial to the development of innovative enterprises. For this reason, AstraZeneca and Wuxi City have equipped I·Campus with high-standard and professional CRO services. For example, among the first batch of enterprises settled in the park, there is the leading CRO service provider Tigermed, and its subsidiary Guanhe Medical technology. These companies can help companies in the park provide professional third-party services such as clinical trial services, new drug R&D services, drug clinical testing services, and medical device testing services. "I·Campus provides us with services such as tax reduction and exemption, investment and financing support, and we also provide clinical trial center laboratory services for settled enterprises. Through complementary advantages, enterprises have achieved positive business development and achieved Win more." said Xu Yi, general manager of Guanhe Pharmaceutical.
Guanhe Pharmaceutical made its debut at the AstraZeneca I·Campus booth at the third CIIE
“Wuxi International Life Science Innovation Park has established a rich ecosystem to support innovative companies. The most significant advantage is that the innovation park is fully focused on Medical and health field. This allows the park to have sufficient industry awareness and deep industry relationships, so that it can fully understand the specific needs of the medical and health field and enterprises, so as to give the best help to the enterprise and accelerate business development." from Singapore David O'Dell, head of Xin'an Medical Technology China, the world's largest artificial intelligence platform company in the field of ECG, said . Within one year of entering I·Campus, Xin'an Medical Technology has received support from third-party suppliers and market partners in the park, and has successfully localized the solution in the Chinese market recently.
The ECG remote AI diagnostic equipment
exhibited by Xin'an Medical Technology, of course, the steady development of the park is also inseparable from the location advantage of the city where it is located . As one of the central cities in the Yangtze River Delta, Wuxi has a sound economic foundation, with an annual GDP exceeding one trillion in 2019 and ranking 14th in the country. In terms of talents, Wuxi has a good advantage. Through industry accumulation, it has gathered more than 10,000 people in the field of life sciences. In terms of educational resources, it has a 211 key university Jiangnan University.
As we all know, the industry linkage effect is also very important for the development of innovative enterprises. Based on the forward-looking planning and layout of , Wuxi currently has industrial institutions such as the Smart Health Industrial Park, the Wuxi Research Institute of Medical Internet of Things, and the Wuxi (National) Software Park, all of which have helped the I·Campus settled enterprises.
is not only that, Wuxi City is also rich in medical resources. Currently, Wuxi City has 10 tertiary hospitals, 104 community service centers, 67 medical device clinical trial specialties, 40 clinical specialties that can carry out drug clinical trials, and 11 medical institutions with GCP qualifications.
It is with the support of the above political, industry, academic, research, medical, investment and other forces that I·Campus continues to attract innovations in life sciences at home and abroad, so I·Campus was handed over at this CIIE The dazzling answer sheet.
Starting from Wuxi, the innovation park model goes to the whole country
At this year’s CIIE, the Hangzhou International Life Science Innovation Park jointly built by AstraZeneca and the Hangzhou Municipal Government was officially unveiled, and ushered in both technology and overflow information. Companies took the lead to settle in. From Wuxi to Hangzhou, the innovation ecology of the International Life Science Innovation Park is continuously expanding to more places.
Hangzhou International Life Science Innovation Park's first batch of enterprises enter the park signing ceremony
"We have planned five regional headquarters across the country, and Hangzhou International Life Science Innovation Park relies on the eastern headquarters. This area mainly focuses on the digital medical industry. It will work with Wuxi in the future Take advantage of the integrated and coordinated development of the Yangtze River Delta to create innovation clusters." Xu Jing, vice president of AstraZeneca China and head of the Digitalization and Business Innovation Department, said that as the construction of other regional headquarters of the innovation park is gradually completed, the innovation park model will Gradually promote to the whole country.
Shenzhi Technology is a leading ultrasonic artificial intelligence company in China, which has newly settled in Hangzhou International Life Science Innovation Park this time. "We have combined traditional medical imaging with artificial intelligence-assisted diagnosis, scanning and other technologies, and developed a series of medical examination products to provide top hospitals, public health and families with Internet remote diagnosis and auxiliary services." Shenzhi Technology CEO Dr. Ruixing Zhu told Artery Network that ’s entry into the Hangzhou International Life Science Innovation Park this time will use the park’s innovation support to deepen the existing cooperation with AstraZeneca in the primary market and accelerate the market sinking of handheld ultrasound products. The majority of patients provide corresponding treatment services.
It is not difficult to find that whether is the R&D demands of medical innovation companies or the resource assistance in the commercialization process, the International Life Science Innovation Park has provided sufficient support, so that innovation and transformation are on the "fast lane" "Z4z. As the settled enterprises continue to achieve new results, the International Life Science Innovation Park is also continuing to attract innovative forces at home and abroad.
"For innovative companies, they choose not a park, but to join an innovation ecosystem. Therefore, they are concerned about whether the ecosystem can make their business models more shape and the landing process faster. "In Xu Jing's view, AstraZeneca leverages the superior resources of its regional headquarters, from Wuxi to Hangzhou, and to the whole country in the future, which is an important measure to continuously improve the ecosystem. and this will help innovative companies obtain more abundant industrial resources, accelerate the deep integration of the medical industry, and develop new forms of medical industry with local characteristics.
Under the guidance of this concept, the International Life Science Innovation Park has done a lot of work. For example, at the CIIE, Sweden's BioVentureHub and the Innovation Park reached a Sino-Swiss medical innovation strategic cooperation, thereby accelerating the creation and promotion of an international cooperation ecosystem. The Wuxi government has also jointly released the "Wuxi International Health Investment Innovation Summit" plan with AstraZeneca, Tigermed, CICC and other companies.Quickly enhance the international influence of Wuxi's biomedical industry.
Starting from Wuxi to the opening of Hangzhou International Life Science Innovation Park, the ecological layout of AstraZeneca's medical innovation has gradually expanded from point to surface. As many innovative companies continue to join, the ecosystem is also continuously iterating and improving. In this process, in addition to the support provided by the innovation park to innovative enterprises, also helped the park expand its innovation development boundaries, thus forming a positive innovation cycle.
spells out the blueprint for future medical innovation
With the rapid development of urbanization and population aging in China, people's demand for health is increasing. More and more medical innovation companies have appeared in this process, and gradually developed and expanded. Behind these enterprises is the rise and growth of batches of medical innovation parks.
Looking back, from the initial provision of basic services such as venues for innovative companies, to now providing full-chain services from R&D to commercialization, the functions of the Medical Innovation Park are becoming increasingly diversified, and are also contributing to the development of local industries. Here comes an extremely important positive impact.
The national level is also contributing to this trend. During the "13th Five-Year Plan" period, six ministries including the Ministry of Industry and Information Technology issued the "Pharmaceutical Industry Development Planning Guide", which clearly stated that governments at all levels need to scientifically plan industrial clusters based on industry development needs, combining local resource endowments and environmental carrying capacity. Under the guidance of the national top-level design strategy requirements, 's domestic biomedical industry has gradually shown a trend of agglomeration. has formed industrial clusters including the Yangtze River Delta region, the Pearl River Delta region, the Bohai Rim region and the Northeast region. In addition, Henan and Hubei in the central region, and Sichuan and Chongqing in the western region also show a good industrial foundation.
The domestic medical innovation environment continues to improve. As a result, innovative companies have achieved rapid development, and the business level has gradually begun to follow the international standards. In this context, Wuxi International Life Science Innovation Park, a government-enterprise cooperation model, appears at the right time. By gathering global resources and wisdom, it is becoming a life science innovation force at home and abroad to expand the Chinese market and link the global market. The best platform.
"Whenever we hear that companies in the park have obtained new financing or have new technological breakthroughs, it is our team's most excited and happy time." Xu Jing said that the innovation park model is still iterating and optimizing, thus Bring more high-quality services to more medical innovation companies, help them move from China to the world, and let the world's enterprises enter China. "Innovation Park welcomes high-quality innovative companies from all over the world to join in and work together to create a blueprint for future medical innovation."
Wuxi International Life Science Innovation Park is the first stop of AstraZeneca's global innovation incubation concept in mainland China, and it is also the first stop of AstraZeneca's global innovation incubation concept in mainland China. An important part of Likang's business innovation strategy. In the future, with the support of local governments, the Innovation Park will closely integrate the characteristics of the regional economy and form a strong synergy with the China Health Internet of Things Innovation Center. With the support of the Global Medical Industry Fund, it will fully help China lead global innovation and promote Chinese innovation Going out of the country, at the same time, it will bring patients a more complete disease management plan and better treatment options throughout the course of the disease, and change the quality of life of patients.
As more innovative companies join the innovation park, what wonderful chapter will AstraZeneca's medical innovation story continue to write? let us wait and see.
nearly
push
recommend
Statement: The intellectual property rights of the contents published by Arterial Network are exclusively owned or held by Arterial Networks and related rights holders. The interview data presented in the article were provided and confirmed by the interviewee. Without permission, any use such as reprinting, extracting, copying, and mirroring is prohibited.
Everything is bitter, only to cross
